Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Pharmathene reports Q2 2009 financials

PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the second quarter and six months ended June 30, 2009.

14 Aug 2009

Cryolife receives 510(k) clearance from FDA for CryoPatch SG pulmonary human cardiac patch

CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CryoPatch((R)) SG pulmonary human cardiac patch.

12 Aug 2009

Research on blood transfusions points to a potential risk of transfusing donated platelets

Doctors have noticed a pattern in performing bone marrow transplants as a cure for diseases involving bone marrow failure: more transfusions before a bone marrow transplant correlates with a higher likelihood of rejection, says James Zimring, MD, PhD, assistant professor of pathology and laboratory medicine at Emory University School of Medicine.

12 Aug 2009

New insights into identifying children at risk for autoimmune brain disorders

A new study by researchers at Columbia University Mailman School of Public Health's Center for Infection and Immunity indicates that pediatric obsessive-compulsive disorder (OCD), Tourette syndrome and/or tic disorder may develop from an inappropriate immune response to the bacteria causing common throat infections.

11 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors.

11 Aug 2009

Researchers launch study into search-and-destroy antigen for deadly skin cancer

UT Southwestern Medical Center researchers are studying a new antigen to see whether it can track down and kill cancer cells in patients with recurring melanoma, the leading cause of skin cancer deaths.

11 Aug 2009

Cephalon, Inc. completes acquisition of Arana Therapeutics

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of all of the outstanding ordinary shares of Australian biotechnology company, Arana Therapeutics Limited. As a result of the acquisition, Arana is now a wholly-owned subsidiary of Cephalon.

10 Aug 2009

Novel approach for developing an AIDS vaccine

Researchers at the Yerkes National Primate Research Center, Emory University, believe conventional vaccine strategies should not be the only avenue explored in the development of an effective AIDS vaccine.

7 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

Reversible cell-specific drug delivery with aptamer-functionalized liposomes

For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug must also spare healthy cells, and - ideally - its effects will be reversible, to cut short any potentially dangerous side effects.

6 Aug 2009

Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

6 Aug 2009

Ichor Medical Systems awarded $3.3 million to develop Alzheimer’s vaccine

Ichor Medical Systems of San Diego has announced that it has been selected to receive a $3.3 million grant award from the National Institute of Neurological Disorders and Stroke (NINDS) for development of a vaccine for Alzheimer’s disease.

6 Aug 2009

Innexus Biotechnology announces business development initiative on lead preclinical candidate

InNexus Biotechnology Inc. announced today that the Company will embark on a business development initiative for DXL625™ (CD20), the Company’s lead preclinical candidate for the prospective treatment of Non-Hodgkin’s Lymphoma and/or Chronic Lymphocytic Leukemia.

6 Aug 2009

Protein DNA repair complex key to avoiding DNA repair mistakes

As the body creates antibodies to fight invaders, a three-protein DNA repair complex called MRN is crucial for a normal gene-shuffling process to proceed properly, University of Michigan research shows.

5 Aug 2009

Discovery of potential candidate protein for cancer vaccines

Researchers at the University of Pittsburgh School of Medicine have learned that some healthy people naturally developed an immune response against a protein that is made in excess levels in many cancers, including breast, lung, and head and neck cancers. The finding suggests that a vaccine against the protein might prevent malignancies in high-risk individuals.

4 Aug 2009

Tiny device to 'sniff out' disease, heart attacks, poison and environmental pollution

Like the sensitive seismographs that can pick up tremors of impending earthquakes long before they strike, a similar invention from Tel Aviv University researchers may change the face of molecular biology.

3 Aug 2009

Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases

A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier.

3 Aug 2009

Mortality rates higher in hepatitis C virus carriers

Hepatitis C virus (HCV) is a blood-borne disease that causes inflammation of the liver and to which there is currently no vaccine available. The World Health Organization (WHO) estimates that 3% of the world's population, approximately 170 million people, are infected with HCV and it is a leading cause of liver cirrhosis, end stage liver disease, hepatocellular carcinoma (HCC) and liver transplantation.

31 Jul 2009

Virulence of pandemic H1N1 virus analyzed

Laboratory studies at Kansas State University and the work of a K-State researcher are making headway in the effort to control the pandemic H1N1 virus.

31 Jul 2009